Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

CDK9 Inhibitors: A Promising Combination Partner in Treating Hematological Malignancies

News

August 9, 2023
PRESS RELEASE: On August 7, 2023, a new research perspective was published in Oncotarget, entitled, “CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies.” continue reading »

AGO2 in T-prolymphocytic Leukemia (T-PLL)

News

August 7, 2023
PRESS RELEASE: On May 4, 2023, a new editorial was published in Oncotarget, entitled, “AGO2 in T-prolymphocytic leukemia: its canonical and noncanonical deregulation and function.” continue reading »

Epigenetically Guided Cancer Therapy: Targeting H3K27me3 Loss in Pediatric Brain Tumors

News

August 2, 2023
PRESS RELEASE: On May 12, 2023, a new editorial paper was published in Oncotarget, entitled, “Targeting H3K27me3 loss in pediatric brain tumors - a perspective on epigenetically guided cancer therapy.” continue reading »

Multiclonality of Estrogen Receptor Expression in Ductal Carcinoma in Situ (DCIS)

News

August 1, 2023
PRESS RELEASE: On July 20, 2023, a new editorial paper was published in Oncotarget, entitled, “Multiclonality of ER expression in DCIS – Implications for clinical practice and future research.” continue reading »

The Obesity Paradox, Metformin and Lung Cancer

Oncotarget

July 27, 2023
In a new editorial, researchers from Instituto Nacional de Cancerología discuss the obesity paradox and its potential therapeutic opportunities in the context of lung cancer. continue reading »